<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01925599</url>
  </required_header>
  <id_info>
    <org_study_id>BAP101</org_study_id>
    <nct_id>NCT01925599</nct_id>
  </id_info>
  <brief_title>BAP1 Testing in Instance Choroidal Nevi or Uveal Melanoma</brief_title>
  <official_title>Identification of Germline BAP1 Mutation In Subjects With Choroidal Nevi or Uveal Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amy C Schefler, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Greater Houston Retina Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The BAP1 trial will examine the blood of patients diagnosed with choroidal nevi or uveal
      melanoma for a germline BAP1 mutation and other genetic markers associated with developing
      malignancy as well as additional sequencing of the uveal melanoma genome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A germline BAP1 mutation predisposes a person to developing uveal melanoma and other cancers.
      If a mutation is discovered, it changes the potential approach to managing the nevus. In the
      presence of a known genomic change associated with aggressive disease, closer follow up and
      more aggressive treatment could preserve the patient's vision and prevent micrometastatic
      spread. This new screening technique will be able to extend the length and quality of life of
      patients with more frequent targeted cancer screens.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Examine the rate of germline BAP1 mutations in young patients, diagnosed with choroidal nevi</measure>
    <time_frame>1 Year</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Choroidal Nevi, Uveal Melanoma</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole Blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients age &gt; 18 years, diagnosed with choroidal nevi or uveal melanoma
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        any person with choroidal nevi

          -  Willingness to provide signed informed consent

          -  Age &gt; 18 years

          -  Diagnosis of choroidal nevi or uveal melanoma

        Threre are no exclusionary criteria for this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy C. Schefler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Retina Consultants Houston</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amy C Schefler, MD</last_name>
    <phone>713-524-3434</phone>
    <email>acsmd@houstonretina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cassie Cone, BA</last_name>
    <phone>713-524-3434</phone>
    <email>ccone@houstonretina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Retina Consultants of Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cassie Cone, BA</last_name>
      <phone>713-524-3434</phone>
      <email>cassandra.cone@houstonretina.com</email>
    </contact>
    <investigator>
      <last_name>Amy C Schefler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Houston</name>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <zip>77494</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cassie Cone, BA</last_name>
      <phone>713-524-3434</phone>
      <email>ccone@houstonretina.com</email>
    </contact>
    <investigator>
      <last_name>Amy Schefler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Houston</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77384</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melisa Bocanegra</last_name>
      <phone>713-524-3434</phone>
      <email>melisa.bocanegra@houstonretina.com</email>
    </contact>
    <investigator>
      <last_name>Amy Schefler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011 Sep;118(9):1881-5. doi: 10.1016/j.ophtha.2011.01.040. Epub 2011 Jun 24. Review.</citation>
    <PMID>21704381</PMID>
  </reference>
  <reference>
    <citation>Singh AD, Kalyani P, Topham A. Estimating the risk of malignant transformation of a choroidal nevus. Ophthalmology. 2005 Oct;112(10):1784-9. Review.</citation>
    <PMID>16154197</PMID>
  </reference>
  <reference>
    <citation>Jensen DE, Rauscher FJ 3rd. Defining biochemical functions for the BRCA1 tumor suppressor protein: analysis of the BRCA1 binding protein BAP1. Cancer Lett. 1999 Sep;143 Suppl 1:S13-7. Review.</citation>
    <PMID>10546591</PMID>
  </reference>
  <reference>
    <citation>Ventii KH, Devi NS, Friedrich KL, Chernova TA, Tighiouart M, Van Meir EG, Wilkinson KD. BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. Cancer Res. 2008 Sep 1;68(17):6953-62. doi: 10.1158/0008-5472.CAN-08-0365.</citation>
    <PMID>18757409</PMID>
  </reference>
  <reference>
    <citation>Matatall KA, Agapova OA, Onken MD, Worley LA, Bowcock AM, Harbour JW. BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma. BMC Cancer. 2013 Aug 5;13:371. doi: 10.1186/1471-2407-13-371.</citation>
    <PMID>23915344</PMID>
  </reference>
  <reference>
    <citation>Abdel-Rahman MH, Pilarski R, Cebulla CM, Massengill JB, Christopher BN, Boru G, Hovland P, Davidorf FH. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet. 2011 Dec;48(12):856-9. doi: 10.1136/jmedgenet-2011-100156. Epub 2011 Sep 22.</citation>
    <PMID>21941004</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2013</study_first_submitted>
  <study_first_submitted_qc>August 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2013</study_first_posted>
  <last_update_submitted>August 4, 2016</last_update_submitted>
  <last_update_submitted_qc>August 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Greater Houston Retina Research</investigator_affiliation>
    <investigator_full_name>Amy C Schefler, MD</investigator_full_name>
    <investigator_title>Director of Ophthalmic Oncology</investigator_title>
  </responsible_party>
  <keyword>Nevus</keyword>
  <keyword>Choroidal Melanoma</keyword>
  <keyword>BAP1 mutation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Uveal Neoplasms</mesh_term>
    <mesh_term>Nevus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

